CIK 0000921299
- Non-accelerated filer
- Smaller reporting company
KYNTRA BIO, INC.
Sign in to watch- Ticker
- KYNB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770357827
- Phone
- +1 415-978-1200
- Business address
- 350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
- Former names
- FIBROGEN INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-08 | Graham Juan Chief Financial Officer | Sale | −2,749 | $21.16 | $58K | 70,213 |
| 2023-03-08 | Graham Juan Chief Financial Officer | Grant or award | +2,899 | 73,112 | ||
| 2023-03-08 | Graham Juan Chief Financial Officer | Grant or award | +4,668 | 77,780 | ||
| 2023-03-08 | Wettig Thane Chief Commercial Officer | Sale | −6,265 | $21.16 | $133K | 104,090 |
| 2023-03-08 | Wettig Thane Chief Commercial Officer | Grant or award | +5,799 | 109,889 | ||
| 2023-03-08 | Wettig Thane Chief Commercial Officer | Grant or award | +9,338 | 119,227 | ||
| 2023-03-02 | Eisner Mark Chief Medical Officer | Sale | −1,187 | $21.87 | $26K | 172,496 |
| 2023-02-21 | Wettig Thane Chief Commercial Officer | Grant or award | +25,000 | 110,355 | ||
| 2023-02-21 | Wettig Thane Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2023-02-21 | Graham Juan Chief Financial Officer | Grant or award | +25,000 | 72,962 | ||
| 2023-02-21 | Graham Juan Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2023-02-21 | Chung Christine SVP, China Operations | Grant or award | +25,000 | 259,873 | ||
| 2023-02-21 | Chung Christine SVP, China Operations | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2023-02-21 | Eisner Mark Chief Medical Officer | Grant or award | +32,500 | 173,683 | ||
| 2023-02-21 | Eisner Mark Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2023-02-21 | Conterno Enrique A Chief Executive Officer | Grant or award | +85,300 | 380,783 | ||
| 2023-02-21 | Conterno Enrique A Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +143,100 | 143,100 | ||
| 2023-01-06 | Conterno Enrique A Chief Executive Officer | Sale | −1,538 | $19.95 | $31K | 295,483 |
| 2022-12-23 | Wettig Thane Chief Commercial Officer | Sale | −734 | $15.80 | $12K | 89,163 |
| 2022-12-12 | Graham Juan Chief Financial Officer | Sale | −1,407 | $14.50 | $20K | 47,962 |
Page 10 of 16 · 320 trades